Sign In
Buy MRKR
$1.45
+0.0300 (+2.11%)
At Close: Jun 03, 2026
Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results
04:05pm, Wednesday, 12'th May 2021
HOUSTON, May 12, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies
HOUSTON, April 27, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherap
Marker Therapeutics Gets A 'Thumbs Up'
06:56am, Sunday, 25'th Apr 2021
Today, we take an in-depth look at clinical-stage immuno-oncology company named Marker Therapeutics. The company has multiple 'shots on goal', heavy insider buying and recently addressed its funding n
Marker Therapeutics: Undervalued Cancer Therapeutics With High Potential
08:20am, Friday, 23'rd Apr 2021
Marker Therapeutics: Undervalued Cancer Therapeutics With High Potential
10 Reddit Penny Stocks Seeing the Most Chatter Today
01:46pm, Monday, 22'nd Mar 2021
Reddit penny stocks continue to be of interest to risky investors and InvestorPlace is looking at the top ones for Monday. The post 10 Reddit Penny Stocks Seeing the Most Chatter Today appeared first
Why Odonate, Marker Therapeutics and Dyadic Are Moving Monday
10:16am, Monday, 22'nd Mar 2021
Odonate Therapeutics, Inc. (NASDAQ: ODT), Dyadic International, Inc. (NASDAQ: DYAI) and Marker Therapeutics, Inc. (NASDAQ: MRKR) are among the early biotech movers in Monday's session. Odonate to Shut
MRKR Stock Price Increases Over 15% Pre-Market: Why It Happened
06:33am, Monday, 22'nd Mar 2021
The stock price of Marker Therapeutics, Inc. (NASDAQ: MRKR) has increased by over 15% pre-market. This is why it happened.
MRKR Stock Price Increased 34.44%: Why It Happened
08:57am, Sunday, 21'st Mar 2021
The stock price of Marker Therapeutics Inc. (NASDAQ: MRKR) increased by 34.44% on March 19. This is why it happened.
FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings
09:52am, Saturday, 20'th Mar 2021
Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the bigges
Why Clovis Oncology, Marker Therapeutics, Alector Are Rallying Friday
12:43pm, Friday, 19'th Mar 2021
Clovis Oncology, Inc. (NASDAQ: CLVS), Marker Therapeutics, Inc. (NASDAQ: MRKR) and Alector, Inc. (NASDAQ: ALEC) are among the biggest biotech gainers Friday. Clovis Jumps On Ovarian Cancer Data: Clovi
MRKR Stock Price Increases Over 20% Pre-Market: Why It Happened
08:13am, Friday, 19'th Mar 2021
The stock price of TapImmune Inc. (NASDAQ: MRKR) increased by over 20% pre-market. This is why it happened.
Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock
04:57pm, Tuesday, 16'th Mar 2021
HOUSTON, March 16, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherap
Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference
07:00am, Monday, 15'th Mar 2021
HOUSTON, March 15, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunother
Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
08:00am, Friday, 12'th Mar 2021
HOUSTON, March 12, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapi
Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
04:10pm, Thursday, 11'th Mar 2021
HOUSTON, March 11, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherap
